BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 31874858)

  • 21. Exploration of the immune cell infiltration-related gene signature in the prognosis of melanoma.
    Zeng Y; Zeng Y; Yin H; Chen F; Wang Q; Yu X; Zhou Y
    Aging (Albany NY); 2021 Jan; 13(3):3459-3482. PubMed ID: 33428606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of an immune and stromal prognostic signature in uveal melanoma to guide clinical therapy.
    Gong Q; Wan Q; Li A; Yu Y; Ding X; Lin L; Qi X; Hu L
    Aging (Albany NY); 2020 Oct; 12(20):20254-20267. PubMed ID: 33100273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel prognostic biomarker LCP2 correlates with metastatic melanoma-infiltrating CD8
    Wang Z; Peng M
    Sci Rep; 2021 Apr; 11(1):9164. PubMed ID: 33911146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The nucleosome remodeling and deacetylase complex has prognostic significance and associates with immune microenvironment in skin cutaneous melanoma.
    Liu X; Wang J
    Int Immunopharmacol; 2020 Nov; 88():106887. PubMed ID: 32799111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses.
    Zhang B; Yang L; Wang X; Fu D
    Gene; 2021 Jan; 764():145105. PubMed ID: 32882333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.
    Erdag G; Schaefer JT; Smolkin ME; Deacon DH; Shea SM; Dengel LT; Patterson JW; Slingluff CL
    Cancer Res; 2012 Mar; 72(5):1070-80. PubMed ID: 22266112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions.
    Nardin A; Wong WC; Tow C; Molina TJ; Tissier F; Audebourg A; Garcette M; Caignard A; Avril MF; Abastado JP; Prévost-Blondel A
    J Invest Dermatol; 2011 Sep; 131(9):1896-905. PubMed ID: 21654834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of prognostic genes and construction of a novel gene signature in the skin melanoma based on the tumor microenvironment.
    Yingjuan W; Li Z; Wei C; Xiaoyuan W
    Medicine (Baltimore); 2021 May; 100(21):e26017. PubMed ID: 34032721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experimentally validated oxidative stress -associated prognostic signatures describe the immune landscape and predict the drug response and prognosis of SKCM.
    Rong D; Su Y; Jia D; Zeng Z; Yang Y; Wei D; Lu H; Cao Y
    Front Immunol; 2024; 15():1387316. PubMed ID: 38660305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma.
    Nakahara S; Fukushima S; Okada E; Morinaga J; Kubo Y; Tokuzumi A; Matsumoto S; Tsuruta-Kadohisa M; Kimura T; Kuriyama H; Miyashita A; Kajihara I; Jinnin M; Ihn H
    J Dermatol Sci; 2020 Jan; 97(1):77-79. PubMed ID: 31843231
    [No Abstract]   [Full Text] [Related]  

  • 31. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological differences between primary and metastatic breast cancer.
    Szekely B; Bossuyt V; Li X; Wali VB; Patwardhan GA; Frederick C; Silber A; Park T; Harigopal M; Pelekanou V; Zhang M; Yan Q; Rimm DL; Bianchini G; Hatzis C; Pusztai L
    Ann Oncol; 2018 Nov; 29(11):2232-2239. PubMed ID: 30203045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Firing Up Cold Tumors.
    Cheng WC; Ho PC
    Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma.
    Mitra S; Lauss M; Cabrita R; Choi J; Zhang T; Isaksson K; Olsson H; Ingvar C; Carneiro A; Staaf J; Ringnér M; Nielsen K; Brown KM; Jönsson G
    Mol Oncol; 2020 May; 14(5):933-950. PubMed ID: 32147909
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Chen Y; Huang Y; Gao X; Li Y; Lin J; Chen L; Chang L; Chen G; Guan Y; Pan LK; Xia X; Guo Z; Pan J; Xu Y; Yi X; Chen C
    Front Immunol; 2020; 11():1620. PubMed ID: 32903763
    [No Abstract]   [Full Text] [Related]  

  • 36. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
    Olbrecht S; Busschaert P; Qian J; Vanderstichele A; Loverix L; Van Gorp T; Van Nieuwenhuysen E; Han S; Van den Broeck A; Coosemans A; Van Rompuy AS; Lambrechts D; Vergote I
    Genome Med; 2021 Jul; 13(1):111. PubMed ID: 34238352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
    Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
    World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy.
    Xie F; Zhang J; Wang J; Reuben A; Xu W; Yi X; Varn FS; Ye Y; Cheng J; Yu M; Wang Y; Liu Y; Xie M; Du P; Ma K; Ma X; Zhou P; Yang S; Chen Y; Wang G; Xia X; Liao Z; Heymach JV; Wistuba II; Futreal PA; Ye K; Cheng C; Xia T
    Clin Cancer Res; 2020 Jun; 26(12):2908-2920. PubMed ID: 31911545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of B-cell density in cutaneous melanoma.
    Ladányi A; Kiss J; Mohos A; Somlai B; Liszkay G; Gilde K; Fejös Z; Gaudi I; Dobos J; Tímár J
    Cancer Immunol Immunother; 2011 Dec; 60(12):1729-38. PubMed ID: 21779876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
    Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
    Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.